Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Flipping the script on macrophages in leiomyosarcoma ONCOIMMUNOLOGY Edris, B., Weiskopf, K., Weissman, I. L., van de Rijn, M. 2012; 1 (7): 1202-1204

Abstract

Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein a (SIRPa) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growth and metastases. Therefore, anti-CD47 mAbs represent a promising targeted immunotherapy for LMS.

View details for DOI 10.4161/onci.20799

View details for Web of Science ID 000316279900033

View details for PubMedCentralID PMC3494646